Study on Sorafenib and Doxorubicin for Advanced Liver Cancer After Sorafenib Treatment

Inclusion Criteria

• Confirmed diagnosis of liver cancer (HCC), excluding certain types like mixed HCC or fibrolamellar variant.
• Previously treated with sorafenib, with evidence that the cancer has progressed.
• Cancer that can be measured using standard criteria.
• No severe liver disease or only mild cirrhosis (Child-Pugh A).
• Expected to live at least 3 more months.
• Aged 18 years or older.
• Good overall health with a performance score of 70% or higher.
• Fully recovered from any previous surgery or radiation, with none in the last 2 weeks.
• May have had certain liver treatments before, as long as the cancer has grown since then or there are untreated areas.
• Must agree to participate and sign a consent form.
• Specific blood test results within normal ranges, including bilirubin, neutrophil count, platelets, and creatinine.
• Can continue treatment for hepatitis B or C, except interferon.
• Well-controlled blood pressure.
• Brain metastases allowed if stable and without seizures.
• Previous radiation to bones allowed if completed over 2 weeks ago.

Exclusion Criteria

• Serious heart conditions, including recent heart attack or severe heart failure.
• Irregular heartbeats needing specific treatments, except beta blockers or digoxin.
• Heart function below normal levels.
• Participation in other experimental studies.
• Previous treatment with certain liver therapies or doxorubicin.
• Pregnant or breastfeeding women.
• Uncontrolled illnesses or psychiatric conditions affecting study participation.
• History of another cancer, except certain skin or cervical cancers, or other solid tumors without active disease.
• Recent bleeding in the esophagus or stomach.
• Use of certain medications like Rifampin or St John's Wort, which must be stopped 4 weeks before starting the study.
• Known HIV positive status.
• History of bleeding disorders.